Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating ...

A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a ...